Clinical outcomes of postdilatation with non-compliant balloons following implantation of drug-eluting stents

doi:10.3969/j.issn.1006-7795.2015.02.024

Abstract

Abstract:

Objective To assess the clinical effects of postdilatation with non-compliant balloons following implantation of drug-eluting stents(DES) in patients with coronary artery disease. Methods From January 2011 to July 2011, 356 consecutive patients underwent postdilatation with non-compliant balloons following implantation of DES at Beijing Anzhen Hospital, Capital Medical University. Via propensity score methodology, these patients were matched with 1 group of 356 patients who underwent DES without postdilatation during the same period. Results The two groups were similar for age, sex, clinical presentation, main risk factors and the features of coronary artery lesions. At 18-month follow-up incidence of major adverse cardiac events(MACE) was 10.1% in the postdilatation treatment group and 15.7% in routine un-postdilatation group(P=0.020), with a significant difference in target vessel revascularization and stent thrombosis(6.2% vs 10.7%, P=0.010; and 1.1% vs 3.7%, P=0.030, respectively).There were no statistical differences in myocardial infarction(AMI) and death rates in the two groups(3.9% vs 4.6%, P=0.700; 1.7% vs 1.3%, P=0.229; and 1.1% vs 1.7%, P=0.760, respectively). Conclusion Postdilatation after DES implantation in patients with coronary artery disease is safe and associated improved clinical outcomes.

Key words: coronary artery disease, drug-eluting stents, postdilatation

CLC Number:

R541.4

Hu Bin, Jia Dean, Fang Zhe, Yang Shiwei, Han Hongya, Xu Xiaohan, Yu Miao, Ma Qian, Shen Hua, Shi Dongmei, Zhou Yujie. Clinical outcomes of postdilatation with non-compliant balloons following implantation of drug-eluting stents[J]. Journal of Capital Medical University, 2015, 36(2): 299-302.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.02.024

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I2/299

References

[1] de Feyter P J, Kay P, Disco C, et al. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography[J]. Circulation, 1999,100(17):1777-1783.
[2] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009)[J].中华心血管病学杂志,2009,37(1):4-25.
[3] Cutlip D E, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials:a case for standardized definitions[J]. Circulation, 2007,115(17):2344-2351.
[4] Brodie B R, Cooper C, Jones M, et al. Is adjunctive balloon postdilatation necessary after coronary stent deployment? Final results from the POSTIT[J]. Catheter Cardiovasc Interv, 2003,59(2):184-192.
[5] Cheneau E, Satler L F, Escolar E, et al. Underexpansion of sirolimus-eluting stents:incidence and relationship to delivery pressure[J]. Catheter Cardiovasc Interve, 2005,65(2):222-226.
[6] Kim J S, Moon J Y, Ko Y G, et al. Intravascular ultrasound evaluation of optimal drug-eluting stent expansion after poststent balloon dilation using a noncompliant balloon versus a semicompliant balloon (from the Poststent Optimal Stent Expansion Trial).[J]. Am J Cardiol, 2008,102(3):304-310.
[7] Pregowski J, Jastrzebski J, Kepka C, et al. Relation between coronary plaque calcium deposits as described by computed tomography coronary angiography and acute results of stent deployment as assessed by intravascular ultrasound[J]. Postepy W Kardiol Interwencyjnej, 2013,9(2):115-120.
[8] Pasceri V, Pelliccia F, Pristipino C, et al. Clinical effects of routine postdilatation of drug-eluting stents[J]. Catheter Cardiovasc Interv, 2014,83(6):898-904.
[9] Gao Z, Yang Y J, Xu B et al. Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients[J]. Chin Med J:Engl, 2008,121(6):513-517.
[10] 李俊峡.心血管疾病介入治疗发展概述及展望[J].解放军医药杂志,2012,24(9):1-6.
[11] 孙盘丽,贾合磊.吡格列酮对非糖尿病患者冠脉内支架术后患者预后的影响[J].中国煤炭工业医学杂志,2012,15(1):31-32.
[12] Wu G Y, Zong G J, Chen J K, et al. Changes of plasma B-type natriuretic peptide levels after high-pressure post-dilation following coronary stent deployment[J]. PLoS One, 2013,8(12):e82357.
[13] Biswas S, Soon K H, Lim Y L. Angiographic and clinical outcomes of stent postdilatation in ST-elevation myocardial infarction[J]. Heart Lung Circ, 2012,21(11):684-688.
[14] Zhang Z J, Marroquin O C, Stone R A, et al. Differential effects of post-dilation after stent deployment in patients presenting with and without acute myocardial infarction[J]. Am Heart J, 2010,160(5):979-986.

[1]	Su Yunjuan, Wang Jingjing, Han Xiaotao, Liu Haiyan, Chen Yongfu, Yang Liu, Wu Qiming. Risk factors and predictive value of Framingham Risk Score of young men with coronary artery disease [J]. Journal of Capital Medical University, 2022, 43(1): 143-148.
[2]	Liu Jinchun, Zheng Xiuhua, Li Ning, Zhang Ruixia, Zhang Haizhu. Predictive factors for the formation of a well-developed coronary collateral circulation in patients with unstable angina pectoris [J]. Journal of Capital Medical University, 2021, 42(4): 642-646.
[3]	Gu Shanshan, Lu Jie, Chen Gang. Diagnostic value of ischemia severity at myocardial perfusion imaging in elderly persons with suspected coronary disease [J]. Journal of Capital Medical University, 2021, 42(1): 26-30.
[4]	Hu Bin, Zhou Yujie, Jia Dean, Qin Zheng, Xu Xiaohan, Yang Shiwei, Zhou Zhimin. Observation on effect of rotational atherectomy followed by drug-eluting stents implantation in patients age ≥65 years with severe calcified coronary lesions [J]. Journal of Capital Medical University, 2021, 42(1): 101-104.
[5]	Li Xiang, Pu Lianmei, Ruan Yang, Li Hong, Jin Zening. The relationship between ADIPOR1 rs7539542 and the susceptibility of coronary artery disease and type 2 diabetes in Han population [J]. Journal of Capital Medical University, 2020, 41(6): 935-942.
[6]	Sun Shuai, Zou Meiping, Liu Qiang, Weng Jianxin. Comparison of drug-eluting stents and cutting balloon in the management of in-stent restenosis [J]. Journal of Capital Medical University, 2017, 38(3): 465-469.
[7]	Wang Dezhao, Ma Ning, Hu Hongyu, Mo Dapeng, Fu Qiang, Chen Wei, Jiang Guiying, Miao Zhongrong, Chen Buxing. Relationship between the lesions of coronary artery and the upper-aortic arteries stenosis [J]. Journal of Capital Medical University, 2016, 37(1): 58-61.
[8]	GU Shanshan, WANG Qian, DONG Wei, JIAO Jian, SU Hang, FU Ying. Clinical study on coronary computed tomography angiography and myocardial perfusion imaging in quantitative assessment of flow-limiting stenoses [J]. Journal of Capital Medical University, 2013, 34(1): 36-42.
[9]	LI Xiaotao;WEI Liye;Ren Yunjun;LI Qiang;XIA Yang;XIA Yue;GUO Xichao. Relationship between serum placental growth factor and coronary collateral circulation [J]. Journal of Capital Medical University, 2012, 33(6): 833-836.
[10]	Wang Shan;Tan Jing;Hua Qi. Effect of Simvastatin on High Sensitivity C-reactive Protein in Serum of Patients with Stable Coronary Artery Disease [J]. Journal of Capital Medical University, 2008, 29(4): 490-492.
[11]	Yang Yi;Yuan Shenyuan;Pan Sufang;Qian Ning. The Relationship between Body Mass Index and the Incidence of Diabetes Mellitus,Coronary Artery Disease and Stroke [J]. Journal of Capital Medical University, 2006, 27(5): 669-671.
[12]	Xu Dong;Zhangjian;Liu Yanhui;Shang Xuebin;Li Xuefeng;Wang Shouyu;Liu Fei;Li Hongli. Short Term Follow-up for Coronary Artery Bypass Grafting Combined with Valve Replacement Surgery [J]. Journal of Capital Medical University, 2006, 27(4): 531-533.
[13]	Wang Xiaoyan;Wang Rui;Du Fenghe . Aspirin Resistance in Patients with Coronary Artery Disease [J]. Journal of Capital Medical University, 2006, 27(3): 372-374.
[14]	Zhao Xiuli;Zhou Yanming;Yang Jinkui;Li Jincheng;Zhang Hui;Wu Ying;Zhang Renhan;Hu Dayi. Clinical Study of Controlled-Release formula of Glipizide in the Treatment of Coronary Artery Disease Complicated with Type 2 Diabetes Mellitus [J]. Journal of Capital Medical University, 2006, 27(1): 78-80.
[15]	Wang Xudong;Fan Zheng;Fu Yan;Yin Hong;Zhai Yanling;Qi Yahui;Zhu Yuqing;Wang Jin;Zhao Xiangyin. 4G/5G Polymorphism at Plasminogen Activator Inhibitor-1 Promoter in Patients with Type Ⅱ Diabetic and Coronary Artery Disease [J]. Journal of Capital Medical University, 2004, 25(2): 223-226.